

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A01/2014

DESPATCHED ON 21ST JANUARY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B8, B44; Cw5, Cw7; DR17, DR4; DQ2, DQ8

Summary of Results					Summary of Results				
Total tested	44	45	45	45	30	32	33	32	
Positive	33	4	44	10	16	2	31	1	
Negative	11	41	1	35	14	30	2	31	
Not Tested	7	6	6	6	19	17	16	17	
% Positive	75.0%	8.9%	97.8%	22.2%	53.3%	6.3%	93.9%	3.1%	
% Negative	25.0%	91.1%	2.2%	77.8%	46.7%	93.8%	6.1%	96.9%	
<b>Consensus</b>	<b>Positive</b>	<b>Negative</b>	<b>Positive</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Positive</b>	<b>Negative</b>	
HLA Antibody (Defined By CDC)	B12, B21	B18+	A3, B7, B27, B22	A9, B57+					
Without DTT					With DTT (Pre-pilot - Not assessed)				Comments
Lab No.	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
112	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
114	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
116	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
117	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
119	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
120	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
126	Negative	Negative	Positive	Positive	NT	NT	NT	NT	
128	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
136	Negative	Negative	Positive	Negative	NT	NT	NT	NT	
139	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
143	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
145	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
147	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
149	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
154	Negative	Negative	Positive	Weak Positive	Negative	Negative	Positive	Negative	
159	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
162	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
164	Positive	Positive	Positive	Negative	Positive	Positive	Negative	Negative	
169	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	
174	Positive	Negative	Positive	Negative	NT	Negative	Positive	Negative	
181	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	
186	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
189	Negative	Negative	Positive	Negative	NT	NT	Positive	NT	
190	NT	NT	NT	NT	NT	NT	NT	NT	
193	Positive	Positive	Positive	Positive	Positive	Negative	Positive	Negative	
195	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
197	NT	NT	NT	NT	NT	NT	NT	NT	
202	NT	NT	NT	NT	NT	NT	NT	NT	
204	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
206	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
209	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
210	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
216	Positive	Negative	Positive	Positive	NT	NT	NT	NT	
223	NT	NT	NT	NT	NT	NT	NT	NT	
227	NT	Negative	Positive	Negative	NT	Negative	Positive	Negative	
229	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
232	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
235	NT	NT	NT	NT	NT	NT	NT	NT	
238	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
243	Positive	Positive	Positive	Negative	NT	NT	NT	NT	
245	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	
252	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
259	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
260	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
262	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
268	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	
284	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
293	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
294	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
297	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A01/2014

DESPATCHED ON 21ST JANUARY 2014

Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Date received	Date tested	Cells used PBL	T-cells	Immunobeaded cells used?	Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						PBL	T-cells		PBL	T-cells	
112	6	1	8	1	1	1	8	1	24-Jan	24-Jan	Yes		No	95		One Lambda	30	60	Stain fix
114	1	1	6	1	1	1	6	1	22-Jan	23-Jan		Yes	Yes			One Lambda	30	60	Fluoroquench
116	6	1	8	4	6	1	8	1	21-Jan	21-Jan		Yes	No	90		Cedarlane	20	60	EB/AO
117	8	1	8	1	NT	NT	NT	NT	23-Jan	23-Jan	Yes		No	60		Pel-Freeze	60	105	Eosin Staining
119	8	1	8	1	1	1	6	1	22-Jan	23-Jan	Yes		No	90		Biorad	30	60	Eosin Staining
120	4	1	8	1	1	1	6	1	22-Jan	23-Jan		Yes	Yes	100		Servibio	30	60	Fluoroquench
126	-	-	100%	75%	NT	NT	NT	NT	14-Jan	14-Jan		Yes	Yes	100		Cedarlane	30	40	EB/AO
128	4	1	8	1	4	1	6	1	24-Jan	28-Jan	Yes		No	90		One Lambda	45	90	
136	1	1	8	1	NT	NT	NT	NT	22-Jan	23-Jan			Yes			In-house	60	60	EB/AO
139	4	1	8	1	4	1	8	1	23-Jan	24-Jan	Yes	Yes	Yes	90	90	Cedarlane	30	60	Eosin Yellow
143	8	2	8	2	NT	NT	NT	NT	23-Jan	24-Jan		Yes	Yes	95		Cedarlane	30	60	Eosin Staining
145	8	-	8	-	NT	NT	NT	NT	22-Jan	23-Jan		Yes	Yes	100		Invitrogen	45	45	EB/AO
147	6	1	8	1	4	1	8	1	22-Jan	22-Jan		Yes	Yes	100		In-house	30	60	Fluoroquench
149	6-8	-	8	-	NT	NT	NT	NT	23-Jan	24-Jan	Yes			85			60	60	Eosin Staining
154	1	1	8	2	1	1	8	1	22-Jan	23-Jan		Yes	No	100	95	Cedarlane	30	60	Eosin Staining
159	4	-	8	-	-	-	8	-	23-Jan	23-Jan		Yes	Yes	80		In-house	30	60	Fluoroquench
162	8	-	8	-	8	-	8	-	22-Jan	23-Jan		Yes	Yes	100		Cedarlane	60	60	Fluoroquench
164									22-Jan	23-Jan		Yes	Yes	80		Servibio	45	90	Fluoroquench
169	6	4	8	4	6	4	8	4	23-Jan	23-Jan		Yes	No	98		One Lambda	35	75	Fluoroquench
174	80%	-	100%	-	NT	-	100%	-	27-Jan	27-Jan	Yes		No	90		One Lambda	60	120	Eosin
181	1	1	8	4	1	1	8	1	22-Jan	22-Jan	Yes			100		Cedarlane	30	45	Fluoroquench
186	8	0	8	4	8	0	8	0	22-Jan	22-Jan		Yes	Yes	99		Invitrogen	30	60	Fluoroquench
189	1	1	6	1	NT	NT	6	NT	22-Jan	23-Jan	Yes		No	88		Biorad	40	40	EB/AO
190	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
193	8	2	8	4	8	1	8	1	22-Jan	22-Jan		Yes	No	99		Cedarlane	30	60	Stain fix
195	4	1	8	1	NT	NT	NT	NT	24-Jan	24-Jan	Yes		No	60		Invitrogen	30	60	Fluoroquench
197	NT	NT	NT	NT	NT	NT	NT	NT	23-Jan	26-Jan			Yes	40	30				
202																			
204	8	1	8	1	4	1	8	1	22-Jan	22-Jan		Yes	No	95		Cedarlane	45	90	Fluoroquench
206	6	1	8	1	6	1	8	1	22-Jan	22-Jan		Yes	Yes	100		Cedarlane	30	45	Fluoroquench
209	4	-	8	-	-	-	2µl = 8 1µl = 1	-	23-Jan	23-Jan	Yes		No	90		Ingen	30	60	Fluoroquench
210	0	0	8	0	0	0	8	0	23-Jan	23-Jan		Yes	Yes	100		Biorad	30	60	
216	6	2	8	4	NT	NT	NT	NT	23-Jan	24-Jan	Yes		No	85		Biorad	30	60	PI
223	NT	NT	NT	NT	NT	NT	NT	NT	14-Jan	14-Jan		Yes	Yes			Biorad	45	60	EB/AO
227	NT	1	8	1	NT	1	8	1	22-Jan	22-Jan		Yes	Yes	98		GTI Diagnostics	30	60	Fluoroquench
229	100%	-	100%	-	-	-	100%	-	23-Jan	24-Jan	Yes		No			Biorad	30	60	
232	30%	0%	60%	0%	NT	NT	NT	NT	23-Jan	24-Jan	Yes		No	80		Biorad	45	60	Fluoroquench
235																			
238	8	1	8	2	8	1	8	1	22-Jan	23-Jan		Yes	No	99		Invitrogen	45	90	EB
243	8	8	8	2	NT	NT	NT	NT	22-Jan	23-Jan	Yes		Yes	90	80	Biorad	30	60	Fluoroquench
245	1	1	6	1	1	1	1	1	22-Jan	22-Jan	Yes	Yes	No	100	100	BAG	30	60	EB/AO
252	1-2	1	6-8	1-2	1	1-2	6-8	1	24-Jan	24-Jan		Yes	Yes	40		Biorad	30	60	
259	-	-	-	-	NT	NT	NT	NT	23-Jan	23-Jan	Yes	Yes	Yes	15	10	Biorad	30	60	AO/PI
260	-	-	++++	-	-	-	++++	-	23-Jan	23-Jan		Yes	Yes	90		Biorad	30	60	EB/AO
262	4	1	8	1	1	1	6	1	22-Jan	22-Jan	Yes	Yes	Yes	100	100	Invitrogen	30	60	Eosin Staining
268	4	1	8	4	6	1	8	1	22-Jan	22-Jan		Yes	No	95		Gentrak	30	60	EB/AO
271	NT	NT	NT	NT	NT	NT	NT	NT	23-Jan	23-Jan	NT	NT	NT	NT	NT	NT	NT	NT	NT
284	8	1	8	6	8	1	8	1	22-Jan	22-Jan		Yes	Yes	98		Cedarlane	40	60	EB/AO
293	4	-	4	-	4	-	4	-	23-Jan	24-Jan		Yes	Yes	50	50	Invitrogen	60	120	Eosin
294	4	0	8	0	NT	NT	NT	NT	22-Jan	22-Jan		Yes	Yes	100		Pel-Freeze	30	30	Fluoroquench
297	4	1	8	1	4	1	6	1	22-Jan	23-Jan	Yes	Yes	Yes	90	90	Cedarlane	30	60	Fluoroquench

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A01/2014

DESPATCHED ON 21ST JANUARY 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B8, B44; Cw5, Cw7; DR17, DR4; DQ2, DQ8

Summary of Results					Summary of Results				
Total tested	29	29	30	30	24	25	24	25	
Positive	21	4	30	10	18	1	24	3	
Negative	8	25	0	20	6	24	0	22	
Not Tested	6	6	5	5	11	10	11	10	
% Positive	72.4%	13.8%	100.0%	33.3%	75.0%	4.0%	100.0%	12.0%	
% Negative	27.6%	86.2%	0.0%	66.7%	25.0%	96.0%	0.0%	88.0%	
Consensus	Not Assessed	Negative	Positive	Not Assessed	Positive	Negative	Positive	Negative	
HLA Antibody (Defined By CDC)	B12, B21	B18+	A3, B7, B27, B22	A9, B57+					
Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
114	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	The evaluation of XM using B cells was difficult due to a very low number of B cells (especially for 2A01 with serum 2)
120	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
126	Negative	Positive	Positive	Positive	NT	NT	NT	NT	
139	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
145	Positive	NT	Positive	Negative	NT	NT	NT	NT	
147	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
154	Positive	Negative	Positive	Weak Positive	Positive	Negative	Positive	Negative	
159	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
162	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Positive	
164	Positive	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
169	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Positive	
186	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Positive	
190	NT	NT	NT	NT	NT	NT	NT	NT	
193	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
195	NT	NT	NT	NT	NT	NT	NT	NT	
197	NT	NT	NT	NT	NT	NT	NT	NT	
204	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
206	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
209	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
210	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
223	NT	NT	NT	NT	NT	NT	NT	NT	
227	NT	Negative	Positive	Negative	NT	Negative	Positive	Negative	Results not reported due to too few B cells of poor viability. Very low cell viability. Samples could not be tested.
238	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
243	Positive	Positive	Positive	Negative	NT	NT	NT	NT	
245	Negative	Negative	Positive	Negative	Negative	Negative	NT	Negative	
252	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
259	Positive	Positive	Positive	Negative	NT	NT	NT	NT	
260	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	
262	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
268	Negative	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
271	NT	NT	NT	NT	NT	NT	NT	NT	
284	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	
293	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
294	Negative	Negative	Positive	Negative	NT	NT	NT	NT	
297	Positive	Negative	Positive	Positive	Positive	Negative	Positive	Negative	

**UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING**

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A01/2014

DESPATCHED ON 21ST JANUARY 2014

Lab No.	Without DTT				With DTT (Pre-pilot - Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
114	1	1	8	1	1	1	8	1	22-Jan	23-Jan	Yes		One Lambda	30	60	Fluoroquen
120	4	1	8	1	4	1	8	1	22-Jan	23-Jan	Yes	100	Servbio	30	60	Fluoroquen
126	-	20%	100%	100%	NT	NT	NT	NT	14-Jan	14-Jan	Yes	100	Cedarlane	30	40	EB/AO
139	8	1	8	1	8	1	8	1	23-Jan	24-Jan	Yes	90	Cedarlane			Eosin Yellow
145	8	NT	8	-	NT	NT	NT	NT	22-Jan	23-Jan	Yes	90	Invitrogen	45	45	EB/AO
147	6	1	8	1	4	1	8	1	22-Jan	22-Jan	Yes	100	In-house	30	60	Fluoroquen
154	4	1	8	2	4	1	8	1	22-Jan	23-Jan	No	95	Cedarlane	30	60	Eosin Staining
159	4	-	8	-	-	-	8	-	23-Jan	23-Jan	Yes	80	In-house	30	60	Fluoroquen
162	8	-	8	4	8	-	8	4	22-Jan	23-Jan	Yes	80	Cedarlane	60	60	Fluoroquen
164									22-Jan	23-Jan	Yes	80	Servbio	45	90	Fluoroquen
169	8	1	8	4	8	1	8	4	23-Jan	23-Jan	Yes	98	One Lambda	35	75	Fluoroquen
186	8	0	8	6	8	0	8	6	22-Jan	22-Jan	Yes	99	Invitrogen	30	60	Fluoroquen
190	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
193	8	1	8	1	8	1	8	1	22-Jan	22-Jan	Yes	99	Cedarlane	30	60	Hb/PI
195	NT	NT	NT	NT	NT	NT	NT	NT	24-Jan	24-Jan	Yes	30	Invitrogen	60	90	Fluoroquen
197	NT	NT	NT	NT	NT	NT	NT	NT			Yes	30				
204	4	1	8	2	2	1	8	1	22-Jan	22-Jan		70	Cedarlane	45	90	Fluoroquen
206	8	1	8	1	8	1	8	1	22-Jan	22-Jan	Yes	100	Cedarlane	30	45	Fluoroquen
209	6	-	8	-	6	-	8	-	23-Jan	23-Jan	Yes	90	Ingen	30	60	Fluoroquen
210	0	0	8	0	0	0	8	0	23-Jan	23-Jan	Yes	90	Biorad	30	60	
223	NT	NT	NT	NT	NT	NT	NT	NT	14-Jan	14-Jan	Yes		Biorad	45	60	EB/AO
227	NT	1	8	1	NT	1	8	1	22-Jan	22-Jan	Yes	98	GTI Diagnostics	30	60	Fluoroquen
238	8	1	8	4	8	1	8	2	22-Jan	23-Jan	Yes	90	Invitrogen	45	90	EB
243	8	6	6	2	NT	NT	NT	NT	22-Jan	23-Jan	Yes	80	Biorad	30	60	Fluoroquen
245	1	1	8	1	1	1	NT	1	22-Jan	22-Jan	Yes	100	BAG	30	45	EB/AO
252	2-4	2	4-6	2-4	2-4	2-4	4-6	1-2	24-Jan	24-Jan	Yes	30	Biorad	30	60	
259	-	-	-	-	NT	NT	NT	NT	23-Jan	23-Jan	Yes	20	Biorad	30	60	AO/PI
260	-	-	++++	-	-	-	++++	-	23-Jan	23-Jan	Yes	70	Biorad	30	60	EB/AO
262	8	1	8	8	8	1	8	1	22-Jan	22-Jan	Yes	100	Invitrogen	60	90	Eosin Staining
268	1	1	6	1	4	1	6	1	22-Jan	22-Jan	Yes	95	Gentrak	30	60	EB/AO
271	NT	NT	NT	NT	NT	NT	NT	NT	23-Jan	23-Jan	NT	NT	NT	NT	NT	NT
284	8	1	8	6	8	1	8	1	22-Jan	22-Jan	Yes	95	Cedarlane	40	60	EB/AO
293	6	-	4	-	6	-	4	-	23-Jan	24-Jan	Yes	70	Invitrogen	60	120	Eosin
294	0	0	8	0	NT	NT	NT	NT	22-Jan	22-Jan	Yes		Pel-Freeze	30	30	Fluoroquen
297	8	1	8	4	8	1	8	1	22-Jan	23-Jan	Yes	90	Cedarlane	30	60	Fluoroquen

EB - ethidium bromide  
AO - acridine orange  
PI - propidium iodide  
Hb - haemoglobin  
CFDA - carboxy-fluorescein diacetate